Editas Medicine
Presence
Editas Medicine is one of the...
Editas Medicine is a company listed under the stock ticker EDIT (US).
Executives
View the org chart displaying its 20 main executives
Most searched biographies at Editas Medicine
- Gilmore O'Neill, Chief Executive Officer and President
- Andrew Hirsch, Director
- Meeta Chatterjee, Director
Popular executive movements at Editas Medicine
- Harry Gill, Senior Vice President, Operations, has left the company (posted on January 3 2024).
- Bruce Eaton, Executive Vice President, Chief Technology Officer and Chief Business Officer, will leave the company on Jan. 2, 2024 (posted on October 12 2023).
- Caren Deardorf has joined the company as Chief Commercial and Strategy Officer (posted on September 26 2023).
Create your alert
to follow the executive moves at Editas Medicine.
Biotechnology
Editas Medicine has 2,281 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Editas Medicine
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar | Editas Medicine
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates | Editas Medicine
- Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events | Editas Medicine
- Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer | Editas Medicine
- Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer | Editas Medicine
- Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease | Editas Medicine
- Editas Medicine Announces Upcoming Investor Events | Editas Medicine
- Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update | Editas Medicine
- Editas Medicine Announces Second Quarter 2023 Results and Business Updates | Editas Medicine
- Editas Medicine Reports Inducement Grant to New Chief Scientific Officer | Editas Medicine
- View more press releases Close
Social media about Editas Medicine
- Editas Medicine on Wikipedia, Google News & Yahoo Finance
- Editas Medicine on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Meeta Chatterjee 
Call Editas Medicine at +1 617...
